Young adults who used both products in the past year, but did not use them on the same occasion, did not show greater risk compared to those who used only one of these products
In a letter to the FDA signed by 13 experts in the field of tobacco harm reduction, the authors urge that any advice on vaping and COVID-19 should be based on recognition of the pronounced difference in risk between smoking and vaping, the difficulty that many face in quitting nicotine use completely, the risks of harmful unintended consequences, and the strong association of smoking with poverty and various forms of disadvantage. In other words, they worry that the promotion of unfounded fears in relation to COVID-19 may drive vapers back to smoking, with destructive consequences for their health
Multiple purchases
Similar content being viewed by others Background Tobacco use, particularly smoking of combustible cigarettes (CCs), remains a global public health problem and a key risk factor for disorders including respiratory diseases [1,2,3,4,5,6,7,8,9,10]
)
